Acumen shareholders elect all director nominees and ratify E&Y as auditor at annual meeting

Acumen Pharmaceuticals, Inc.

All three Class I director nominees elected: Kimberlee C. Drapkin, Jeffrey Ives (Ph.D.), Sean Stalfort; broker non-votes of 5,658,008.
Ratification of Ernst & Young as independent auditor received 34,702,393.73 votes for, 761.18 against, 165 abstentions.
Approximately 85.69% of outstanding shares (34,703,319.92 of 40,496,512) were present or represented at the meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.